Tip os
Log ind
Britt Meelby Jensen.jpg
Foto: Zealand Pharma PR

Zealand CEO: cancelled agreement is positive news

Top picks in English:

Swiss drug group Helsinn has returned the rights to a Zealand-developed drug to the Danish company and thus, cancelled an almost nine year old license agreement. However, Zealand’s CEO Britt Meelby Jensen is far from pessimistic.


BY MARTIN HAVTORN PETERSEN
Offentliggjort 14.06.17 kl. 20:42

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Here is what Danish drug companies pay their workers

Løn Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Novo will no longer offer price guidance

Top picks in English:

Novo Nordisk will no longer announce the expected price development for its products on the US market.

ALK CEO: We call the FDA on a daily basis

Top picks in English:

Denmark’s ALK is ready to go “full steam” in the launch of a promising tablet against house dust mite allergy on the US market as early as this year. The only obstacle is a formal handover of the marketing permit from former partner Merck, which could push the launch into 2018.

Bioporto CEO despite growing deficit: ”A fantastic six months”

Top picks in English:

Bioporto’s sales of antibodies and the kidney test NGAL for research use have grown rapidly in 2017. Despite this, the company is forced to downgrade its financial expectations, now expecting a larger deficit for the year. But there is a perfectly good reason for that, explains the CEO.

Novo expands its executive team

Top picks in English:

Novo Nordisk has promoted two of its regional directors to its executive management team, which has undergone a slew of changes in the past year.

Darzalex is still the “star of the show” for Genmab

Top picks in English:

Genmab’s Darzalex royalties now cover the company’s operating costs and in addition to that, the cancer drug continues its expansion to new markets. And according to CEO, Jan van de Winkel, Genmab could potentially raise its guidance this year.

Forsiden lige nu

Novo Nordisks store håb overgår ærkerivalen

Novo Nordisk flag-version2.jpg Medicinal & Biotek:

Novo Nordisks ugentlige GLP-1-analog semaglutid har vist sig mere effektiv end det lignende produkt Trulicity fra ærkerivalen Eli Lilly i et klinisk studie.

Nyt Novo-præparat spås store muligheder

Medicinal & Biotek:

Analytikere har stor tiltro til nyt Novo-produkt efter lovende resultater.

Veloxis nedjusterer forventninger trods fremgang over hele linjen

Medicinal & Biotek:

De første seks måneder af året har budt på fremgang på top- og bundlinje hos biotekselskabet Veloxis Pharmaceuticals.

Krænkelse af Coloplast-patent får betydelige konsekvenser

Medico & Rehab:

Der trækker op til en større erstatningsrunde til Coloplast, efter selskabet har vundet to patentsager i løbet af sommeren, lyder det fra selskabets adm. direktør Lars Rasmussen.

Medicinrådet mangler formænd til kræftråd

Medicinal & Biotek:

Fire fagudvalg under Danske Regioners Medicinråd står uden formand, da det er svært at finde egnede kandidater, der lever op til rådets habilitetsregler.

Coloplast-direktør: Kina er kommet op i gear

Medico & Rehab:

Der har været godt gang i Coloplasts kinesiske forretning i tredje kvartal, hvor året ellers startede med negativ vækst i selskabets sårplejedivision. Den positive udvikling fortsætter ind i fjerde kvartal, vurderer selskabets finansdirektør Anders Lonning-Skovgaard.

ANNONCE
ANNONCE


ANNONCE